The Centers for Medicare & Medicaid Services yesterday proposed that Medicare cover monoclonal antibodies that target amyloid to treat Alzheimer’s disease for beneficiaries enrolled in qualifying clinical trials. The Food and Drug Administration last June approved the first such Alzheimer’s treatment, Biogen’s Aduhelm (aducanumab), using its accelerated approval pathway. 

“This proposed National Coverage Determination is the result of robust evidence analysis conducted through a thorough review process that found while there may be the potential for promise with this treatment, there is also the potential for harm to patients,” said CMS Chief Medical Officer Lee Fleisher, M.D. “This harm may range from headaches, dizziness, and falls, to other potentially serious complications such as brain bleeds.”

Under the proposed NCD, Medicare would cover the drug, related services and other routine costs, which may include PET scans if required by a trial protocol, CMS said. The agency will accept comments on the proposed NCD for 30 days.

Related News Articles

Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…
Headline
The AHA today expressed support for the Medicare Mental Health Inpatient Equity Act, a bill that would eliminate the 190-day lifetime limit on inpatient…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare…
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud…